Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 65.62
CLDX's Cash to Debt is ranked higher than
51% of the 931 Companies
in the Global Biotechnology industry.

( Industry Median: 61.14 vs. CLDX: 65.62 )
Ranked among companies with meaningful Cash to Debt only.
CLDX' s Cash to Debt Range Over the Past 10 Years
Min: 3.52  Med: 71.59 Max: No Debt
Current: 65.62
Equity to Asset 0.86
CLDX's Equity to Asset is ranked higher than
77% of the 703 Companies
in the Global Biotechnology industry.

( Industry Median: 0.69 vs. CLDX: 0.86 )
Ranked among companies with meaningful Equity to Asset only.
CLDX' s Equity to Asset Range Over the Past 10 Years
Min: -0.12  Med: 0.83 Max: 0.92
Current: 0.86
-0.12
0.92
Interest Coverage No Debt
CLDX's Interest Coverage is ranked higher than
95% of the 385 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. CLDX: No Debt )
Ranked among companies with meaningful Interest Coverage only.
CLDX' s Interest Coverage Range Over the Past 10 Years
Min: N/A  Med: 10000.00 Max: 9999.99
Current: No Debt
N/A
9999.99
F-Score: 4
Z-Score: 2.25
M-Score: -2.09
WACC vs ROIC
28.29%
-1041.62%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -2363.44
CLDX's Operating margin (%) is ranked lower than
85% of the 728 Companies
in the Global Biotechnology industry.

( Industry Median: -65.33 vs. CLDX: -2363.44 )
Ranked among companies with meaningful Operating margin (%) only.
CLDX' s Operating margin (%) Range Over the Past 10 Years
Min: -3414.11  Med: -493.44 Max: -13.79
Current: -2363.44
-3414.11
-13.79
Net-margin (%) -2320.69
CLDX's Net-margin (%) is ranked lower than
85% of the 728 Companies
in the Global Biotechnology industry.

( Industry Median: -63.93 vs. CLDX: -2320.69 )
Ranked among companies with meaningful Net-margin (%) only.
CLDX' s Net-margin (%) Range Over the Past 10 Years
Min: -3292.81  Med: -505.66 Max: -5.41
Current: -2320.69
-3292.81
-5.41
ROE (%) -41.25
CLDX's ROE (%) is ranked lower than
57% of the 856 Companies
in the Global Biotechnology industry.

( Industry Median: -30.96 vs. CLDX: -41.25 )
Ranked among companies with meaningful ROE (%) only.
CLDX' s ROE (%) Range Over the Past 10 Years
Min: -4205.83  Med: -67.06 Max: -3.4
Current: -41.25
-4205.83
-3.4
ROA (%) -36.78
CLDX's ROA (%) is ranked lower than
60% of the 935 Companies
in the Global Biotechnology industry.

( Industry Median: -26.04 vs. CLDX: -36.78 )
Ranked among companies with meaningful ROA (%) only.
CLDX' s ROA (%) Range Over the Past 10 Years
Min: -120  Med: -42.35 Max: -2.02
Current: -36.78
-120
-2.02
ROC (Joel Greenblatt) (%) -1119.07
CLDX's ROC (Joel Greenblatt) (%) is ranked lower than
63% of the 899 Companies
in the Global Biotechnology industry.

( Industry Median: -363.62 vs. CLDX: -1119.07 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
CLDX' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -1156.55  Med: -530.69 Max: -10.72
Current: -1119.07
-1156.55
-10.72
Revenue Growth (3Y)(%) -33.90
CLDX's Revenue Growth (3Y)(%) is ranked lower than
81% of the 478 Companies
in the Global Biotechnology industry.

( Industry Median: 4.50 vs. CLDX: -33.90 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
CLDX' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -67.2  Med: -12.70 Max: 71.9
Current: -33.9
-67.2
71.9
EBITDA Growth (3Y)(%) 10.40
CLDX's EBITDA Growth (3Y)(%) is ranked higher than
65% of the 498 Companies
in the Global Biotechnology industry.

( Industry Median: -0.80 vs. CLDX: 10.40 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
CLDX' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -32.9  Med: -2.10 Max: 22.5
Current: 10.4
-32.9
22.5
EPS Growth (3Y)(%) 8.60
CLDX's EPS Growth (3Y)(%) is ranked higher than
67% of the 488 Companies
in the Global Biotechnology industry.

( Industry Median: -2.90 vs. CLDX: 8.60 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
CLDX' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -64.8  Med: -6.90 Max: 134.8
Current: 8.6
-64.8
134.8
» CLDX's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-08-10)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2015

CLDX Guru Trades in Q2 2015

Murray Stahl 26,335 sh (unchged)
First Eagle Investment 559,542 sh (unchged)
Joel Greenblatt Sold Out
Paul Tudor Jones Sold Out
Columbia Wanger 2,591,703 sh (-7.46%)
» More
Q3 2015

CLDX Guru Trades in Q3 2015

Columbia Wanger 3,109,615 sh (+19.98%)
First Eagle Investment 559,542 sh (unchged)
Murray Stahl 26,335 sh (unchged)
» More
Q4 2015

CLDX Guru Trades in Q4 2015

Paul Tudor Jones 15,857 sh (New)
Columbia Wanger 3,610,008 sh (+16.09%)
First Eagle Investment 579,542 sh (+3.57%)
Murray Stahl 26,335 sh (unchged)
» More
Q1 2016

CLDX Guru Trades in Q1 2016

Murray Stahl 26,335 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with CLDX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 1.36
CLDX's P/B is ranked higher than
84% of the 842 Companies
in the Global Biotechnology industry.

( Industry Median: 3.38 vs. CLDX: 1.36 )
Ranked among companies with meaningful P/B only.
CLDX' s P/B Range Over the Past 10 Years
Min: 1.1  Med: 5.26 Max: 50.74
Current: 1.36
1.1
50.74
P/S 72.73
CLDX's P/S is ranked lower than
82% of the 671 Companies
in the Global Biotechnology industry.

( Industry Median: 10.84 vs. CLDX: 72.73 )
Ranked among companies with meaningful P/S only.
CLDX' s P/S Range Over the Past 10 Years
Min: 1.67  Med: 33.14 Max: 975.38
Current: 72.73
1.67
975.38
Current Ratio 9.75
CLDX's Current Ratio is ranked higher than
75% of the 905 Companies
in the Global Biotechnology industry.

( Industry Median: 4.73 vs. CLDX: 9.75 )
Ranked among companies with meaningful Current Ratio only.
CLDX' s Current Ratio Range Over the Past 10 Years
Min: 0.56  Med: 6.56 Max: 15
Current: 9.75
0.56
15
Quick Ratio 9.75
CLDX's Quick Ratio is ranked higher than
76% of the 905 Companies
in the Global Biotechnology industry.

( Industry Median: 4.54 vs. CLDX: 9.75 )
Ranked among companies with meaningful Quick Ratio only.
CLDX' s Quick Ratio Range Over the Past 10 Years
Min: 0.56  Med: 6.56 Max: 15
Current: 9.75
0.56
15
Days Sales Outstanding 64.60
CLDX's Days Sales Outstanding is ranked higher than
51% of the 602 Companies
in the Global Biotechnology industry.

( Industry Median: 65.97 vs. CLDX: 64.60 )
Ranked among companies with meaningful Days Sales Outstanding only.
CLDX' s Days Sales Outstanding Range Over the Past 10 Years
Min: 1.43  Med: 13.35 Max: 89.44
Current: 64.6
1.43
89.44

Valuation & Return

vs
industry
vs
history
Price/Net Cash 1.63
CLDX's Price/Net Cash is ranked higher than
89% of the 495 Companies
in the Global Biotechnology industry.

( Industry Median: 5.42 vs. CLDX: 1.63 )
Ranked among companies with meaningful Price/Net Cash only.
CLDX' s Price/Net Cash Range Over the Past 10 Years
Min: 2.94  Med: 7.99 Max: 22.34
Current: 1.63
2.94
22.34
Price/Net Current Asset Value 1.59
CLDX's Price/Net Current Asset Value is ranked higher than
90% of the 613 Companies
in the Global Biotechnology industry.

( Industry Median: 5.24 vs. CLDX: 1.59 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
CLDX' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 2.77  Med: 7.78 Max: 16.63
Current: 1.59
2.77
16.63
Price/Tangible Book 1.52
CLDX's Price/Tangible Book is ranked higher than
85% of the 776 Companies
in the Global Biotechnology industry.

( Industry Median: 4.11 vs. CLDX: 1.52 )
Ranked among companies with meaningful Price/Tangible Book only.
CLDX' s Price/Tangible Book Range Over the Past 10 Years
Min: 2.07  Med: 6.77 Max: 10.26
Current: 1.52
2.07
10.26
Price/Median PS Value 2.22
CLDX's Price/Median PS Value is ranked lower than
83% of the 574 Companies
in the Global Biotechnology industry.

( Industry Median: 0.95 vs. CLDX: 2.22 )
Ranked among companies with meaningful Price/Median PS Value only.
CLDX' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.09  Med: 1.13 Max: 14.22
Current: 2.22
0.09
14.22
Earnings Yield (Greenblatt) (%) -116.30
CLDX's Earnings Yield (Greenblatt) (%) is ranked lower than
94% of the 897 Companies
in the Global Biotechnology industry.

( Industry Median: -7.90 vs. CLDX: -116.30 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
CLDX' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -460.4  Med: 391.85 Max: 1732
Current: -116.3
-460.4
1732

More Statistics

Revenue(Mil) $5
EPS $ -1.31
Beta3.56
Short Percentage of Float31.09%
52-Week Range $2.96 - 29.94
Shares Outstanding(Mil)98.70

Analyst Estimate

Dec16 Dec17 Dec18
Revenue(Mil) 4 3 115
EPS($) -1.33 -1.37 -0.76
EPS without NRI($) -1.33 -1.37 -0.76

Business Description

Industry: Biotechnology » Biotechnology
Compare:NAS:RPTP, NAS:ARNA, NAS:BPMC, NAS:XBIT, XKRX:031390, XKRX:049960 » details
Traded in other countries:TCE1.Germany,
Celldex Therapeutics Inc was incorporated in Delaware. The Company is a biopharmaceutical company focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other difficult-to-treat diseases. Its drug candidate, rindopepimut (CDX-110), is an immunotherapeutic vaccine that targets the tumor-specific molecule, epidermal growth factor receptor variant III (EGFRvIII). EGFRvIII is a mutated form of the epidermal growth factor receptor (EGFR) that is only expressed in cancer cells and not in normal tissue and can directly contribute to cancer cell growth. Its other drug candidates include CDX-011 and CDX-1127. CDX-011 is an antibody-drug conjugate (ADC) that consists of a fully-human monoclonal antibody, CR011, linked to a potent cell-killing drug, monomethyl-auristatin E (MMAE). The CR011 antibody specifically targets glycoprotein NMB (GPNMB) that is expressed in a variety of human cancers including breast cancer. In December 2011, it completed enrollment of EMERGE, a randomized Phase 2b study of CDX-011 in patients with heavily pre-treated, advanced, GPNMB-positive breast cancer. It has additional clinical and preclinical programs, including CDX-1401, an APC Targeting Technology program, CDX-301, an immune cell mobilizing agent and dendritic cell growth factor and CDX-1135, a molecule that inhibits a part of the immune system called the complement system. The Company's products are derived from a broad set of complementary technologies which have the ability to utilize the human immune system and enable the creation of therapeutic agents. It is using these technologies to develop targeted immunotherapeutics comprised of antibodies, adjuvants and monotherapies and antibody-drug conjugates that prevent or treat cancer and other diseases that modify undesirable activity by the body's own proteins or cells. A number of its immunotherapeutic and antibody-drug conjugate drug candidates are in various stages of clinical trials. The Company faces competition from pharmaceutical and biotechnology companies both in the United States and abroad which include Arbor Pharmaceutics, Inc., AstraZeneca PLC, Bayer, Celgene Corporation, Eisai Inc., Eli Lilly and Company, Medigene AG, Northwest Biotherapeutics, Inc., Pfizer Inc., and Roche. In the United States, vaccines and immunotherapeutics for human use are subject to The Food and Drug Administration (FDA) approval as 'biologics' under the Public Health Service Act and 'drugs' under the Federal Food, Drug and Cosmetic Act.
» More Articles for CLDX

Headlines

Articles On GuruFocus.com
Cantor Fitzgerald and Brean Capital Positive on Celldex Therapeutics Following Positive Data For Bra Jun 01 2015 
Monday Morning Pre-Market Insights: Celldex Therapeutics, Celladon Corp, CTI BioPharma Corp, TG Ther Jun 01 2015 
Roth Capital Weighs In On 5 Biotech Stocks to Watch Apr 05 2015 
Cowen & Co Remains Bullish on Celldex Therapeutics Following FDA 'Breakthrough' Approval Feb 24 2015 
CLDX up 223%, Cohen Gains Big Apr 23 2013 
Steve Cohen Increases Celldex Up 145% Apr 06 2013 
5 Resilient Biotech Stocks to Buy for 2012 Feb 28 2012 
CELLDEX THERAPEUTICS, INC (CLDX) CEO Anthony S Marucci buys 12,000 Shares Sep 13 2010 
Weekly CFO Buys Highlight: GNMK, RTIX, BKOR, PTEK, CLDX Sep 12 2010 
CELLDEX THERAPEUTICS, INC Reports Operating Results (10-Q) Aug 05 2010 

More From Other Websites
Celldex Therapeutics Initiates Phase 1/2 Study of Glembatumumab Vedotin in Squamous Cell Lung Cancer Apr 27 2016
Celldex Therapeutics Initiates Phase 1/2 Study of Glembatumumab Vedotin in Squamous Cell Lung Cancer Apr 27 2016
4 Biotech Stocks to Buy at Beaten Down Prices Apr 26 2016
Get The Jump On Next Week With These 4 Trending Small Cap Stocks Apr 22 2016
This Biotech Is Up 300% In Two Months Apr 20 2016
Celldex Therapeutics Presents Data Supporting the Clinical Development of Glembatumumab Vedotin and... Apr 20 2016
Celldex Therapeutics Presents Data Supporting the Clinical Development of Glembatumumab Vedotin and... Apr 20 2016
Celldex Therapeutics Presents Favorable Safety Profile and Immune Response Data from Phase 1/2 Study... Apr 18 2016
Celldex Therapeutics Presents Favorable Safety Profile and Immune Response Data from Phase 1/2 Study... Apr 18 2016
4 Small Cap Stocks That Have To Be On Your Watchlist Today Apr 14 2016
Six Technologies That Will Change Healthcare Apr 07 2016
iShares Nasdaq Biotechnology ETF (IBB) Had Strong Start to April Apr 05 2016
Biotech's Top 5 Stock Winners, And Losers, In Q1 2016 Mar 31 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK